Search results
Showing 721 to 735 of 1257 results for pathway
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)
NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .
NICE has developed a medtech innovation briefing (MIB) on Neon EEG electrode for EEG monitoring in newborns .
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.
Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.
maternal risk factors, neonatal needs, and stage of the maternity care pathway). - Environmental factors (for example, local geography...
Evidence-based recommendations on the Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters.
Learning disabilities and behaviour that challenges: service design and delivery (NG93)
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
months. There are no clinical trials to define the optimal rehabilitation pathway following hip fracture for these people and therefore...
NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis .
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Getting medicines to NHS patients faster with aligned decisions with the MHRA
access medicines up to 6 months faster through an aligned MHRA and NICE pathway. Other ways to listen Our NICE talks podcasts are...